United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?
Martine Rothblatt exercised options at $135.42 and sold at $530.42 under a pre-established Rule 10b5-1 plan, reducing her stake by just 1% while maintaining $353.1 million in equity value.
Overview
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corporation (NASDAQ:UTHR), sold 9,500 shares of common stock on July 27, 2026, for proceeds totaling $5.0 million. SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($530.42); post-transaction value based on July 27, 2026 market close ($527.94).
Details
United Therapeutics is a specialized biotechnology company with a market capitalization of $22.4 billion, generating $3.2 billion in trailing twelve-month (TTM) revenue and reporting a high net income of $1.3 billion. The company maintains a focused commercial strategy centered on high-value therapeutic solutions for life-threatening conditions, positioning itself as a leader in the pulmonary hypertension treatment space with a diversified international presence.
Source
Originally published at www.fool.com.